

What Is Claimed Is:

1. A method of stimulating angiogenesis in a mammal, comprising administering to said mammal an effective amount of a polynucleotide encoding CTGF-2, or an active fragment or derivative thereof.
2. The method of claim 1, wherein said administered polynucleotide is contained in an adenoviral vector.
3. The method of claim 1, wherein the mammal has ischemia.
4. The method of claim 1, wherein the mammal has restenosis.
5. The method of claim 1, wherein said polynucleotide is delivered to the heart.
6. The method of claim 2, wherein the adenoviral vector is pTG14550 deposited with the Pasteur Institute as deposit number CNCM I-2695.
7. The method of claim 1, wherein the polynucleotide is administered intramuscularly.
8. The method of claim 1, wherein the polynucleotide is administered intravenously.
9. The method of claim 1, wherein the mammal is treated for limb revascularization.
10. The method of claim 9, wherein the limb is a leg.
11. The method of claim 9, wherein the limb is an arm.
12. The method of claim 1, wherein the mammal is human.
13. The method of claim 1, wherein the polynucleotide is administered with a pharmaceutically acceptable carrier selected from the group consisting of:

10277207-01670660

- (a) saline,
- (b) buffered saline,
- (c) dextrose,
- (d) water,
- (e) glycerol,
- (f) ethanol, and
- (g) combinations of the above.

14. The method of claim 1, wherein the polypeptide or active fragment or derivative thereof is fused to human serum albumin

15. A method of stimulating angiogenesis in a mammal, comprising administering to said mammal an effective of a CTGF-2 polypeptide, or an active fragment or derivative thereof.

16. The method of claim 15, wherein the mammal has ischemia.

17. The method of claim 15, wherein the mammal has restenosis.

18. The method of claim 15, wherein the mammal is human

19. The method of claim 18, wherein the polypeptide or active fragment or derivative thereof is fused to human serum albumin.

20. The method of claim 15, wherein the mammal is treated for limb revascularization.

21. The method of claim 20, wherein the limb is a leg.

22. The method of claim 20, wherein the limb is an arm.

23. The method of claim 15, wherein the polynucleotide is administered with a pharmaceutically acceptable carrier selected from the group consisting of:

- (a) saline,

(b) buffered saline,
(c) dextrose,
(d) water,
(e) glycerol,
(f) ethanol, and
(g) combinations of the above.

24. A method of inhibiting tumor growth by administering an antibody or antibody fragment that specifically binds to CTGF-2.

25. An antibody or antibody fragment that specifically binds to a protein whose sequence consists of the protein encoded by the cDNA contained in ATCC Deposit No. 75804.

26. An antibody or antibody fragment that specifically binds to a protein whose sequence consists of SEQ ID NO:2 (as shown in Figures 1A-B).

27. An antibody or antibody fragment that specifically binds to a protein whose sequence consists of SEQ ID NO:7 (as shown in Figures 11A-C).